Free Trial

Pulmonx Q2 2023 Earnings Report

Pulmonx logo
$8.96 +0.18 (+2.05%)
As of 02/21/2025 04:00 PM Eastern

Pulmonx EPS Results

Actual EPS
-$0.43
Consensus EPS
-$0.43
Beat/Miss
Met Expectations
One Year Ago EPS
-$0.40

Pulmonx Revenue Results

Actual Revenue
$17.20 million
Expected Revenue
$15.86 million
Beat/Miss
Beat by +$1.34 million
YoY Revenue Growth
+23.30%

Pulmonx Announcement Details

Quarter
Q2 2023
Time
After Market Closes

Conference Call Resources

Conference Call Audio

Pulmonx Earnings Headlines

Pulmonx (LUNG) Gets a Buy from Piper Sandler
Market down? Do this now.
During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now, history is repeating itself. Here's the truth: Tariffs create uncertainty. Uncertainty drives investors to gold. And gold prices rise as a result. It's a cycle that's already beginning again—and it's your chance to profit. Why wait? Greed isn't always a bad thing—especially when it comes to protecting and growing your wealth. The smartest investors are already moving their money into gold, and you should too.
Pulmonx (LUNG) Receives a Buy from Stifel Nicolaus
See More Pulmonx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Pulmonx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pulmonx and other key companies, straight to your email.

About Pulmonx

Pulmonx (NASDAQ:LUNG), a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

View Pulmonx Profile

More Earnings Resources from MarketBeat